Person: KAYA, HANDAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KAYA
First Name
HANDAN
Name
19 results
Search Results
Now showing 1 - 10 of 19
Publication Metadata only Neoadjuvan kemoterapi uygulanan meme kanserli olgularda güvenli tümör-meme ucu mesafesini meme MR öngörebilir mi?(2022-02-24) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; BUĞDAYCI, ONUR; KAYA, HANDAN; AKOĞLU, HALDUN; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., BUĞDAYCI O., KAYA H., AKIN TELLİ T., AKOĞLU H., GÜLLÜOĞLU M. B.Publication Metadata only Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma(SPRINGER, 2020) KAYA, HANDAN; Sahin Ozkan, Hulya; Ugurlu, Mustafa Umit; Yumuk, Perran Fulden; Kaya, HandanTumor immune microenvironment (TIME) is a significant prognostic parameter for triple negative breast carcinomas (TNBC) due to being a target for immunotherapeutic agents and its essential role during the cancer immunoediting process. In this study, CD8, FOXP3, CD163, PD-L1/SP142 and PD-L1/SP263 antibodies were examined in a sample of 51 TNBC cases. Patients who received neoadjuvant therapy were excluded. CD8, FOXP3 and CD163 antibodies were evaluated separately in intratumoral area (ITA) and tumor stroma (TS). PD-L1 status was also examined in tumor cells (TC) and immune cells (IC) using both SP142 and SP263 antibodies. In multivariate Cox regressions, the only antibody that was found to be significantly associated with survival was SP142. SP142-positivity in TC and IC was related to increased overall survival. Higher CD163 expression in ITA and SP263-positivity in IC were associated with younger age. Lymphatic/angioinvasion was more frequent in cases with negative/low CD8 and FOXP3 expressions. Moreover, metastatic axillary lymph node(s) was associated with negative/low FOXP3 expression in TS. CD8, FOXP3, CD163, SP142 and SP263 expressions were positively correlated with each other, except a mild discordance caused by CD163 in ITA. Although PD-L1 status with both SP142 and SP263 antibodies were concordant in the majority of cases, 33.3% and 13.7% of the cases showed SP142-negative/SP263-positive pattern in TC and IC respectively. In conclusion, we suggest that composition, density and localization of the immune cells and the check point molecules are important prognostic parameters in TNBC. Immunohistochemistry can be used as an accessible and less expensive tool to demonstrate TIME.Publication Metadata only Meme kanserinde neoadjuvan kemoterapi sonrası es-zamani: Rekonstrüksiyon güvenli midir? 5 yıllık tek merkez onkolojik sonuçlar(2022-09-18) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; SAÇAK, BÜLENT; AKDENİZ DOĞAN, ZEYNEP DENİZ; KAYA, HANDAN; BUĞDAYCI, ONUR; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., SAÇAK B., AKDENİZ DOĞAN Z. D., HAYTAOĞLU A. A., KAYA H., BUĞDAYCI O., AKIN TELLİ T., ÖZGEN Z., GÜLLÜOĞLU M. B.Publication Metadata only Arşivlenmiş RNA Örneklerinin Gen Ekspresyon Analizleri Açısından Performansının Değerlendirilmesi Üzerine Metodolojik Çalışma(2023-01-01) GÜLLÜ AMURAN, GÖKÇE; PEKER EYÜBOĞLU, İREM; KAYA, HANDAN; AKKİPRİK, MUSTAFA; GÜLLÜ AMURAN G., POLAT B., PEKER EYÜBOĞLU İ., ÖZMEN T., KAYA H., AKKİPRİK M.Publication Metadata only Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy [Valor predictivo de los índices 18F-FDG PET/TC sobre la carga tumoral residual en pacientes con cáncer de mama extenso tratadas con quimioterapia neoadyuvante](Ediciones Doyma, S.L., 2021) KAYA, HANDAN; Başoğlu T., Özgüven S., Şahin Özkan H., Çınar M., Köstek O., Can Demircan N., Arıkan R., Akın Telli T., Ercelep Ö., Kaya H., Öneş T., Yusuf Erdil T., Ümit Uğurlu M., Dane F., Fulden Yumuk P.Aim: We investigated the correlation between 18F-FDG PET/CT indices and pathological response in breast cancer treated with neoadjuvant chemotherapy (NACT) which was scored with Residual Cancer Burden (RCB) system after surgery. Our aim is to detect extensive residual cancer burden earlier by using PET/CT indices. Methods: Characteristics of patients were retrieved retrospectively. Baseline maximum Standart Uptake Value (SUVmax), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) indices and reduction rate (RR) between baseline and interim evaluation were calculated with FDG PET/CT scan. All patients were evaluated according to RCB scores after surgery. Pathological responses and PET/CT measurement results were analyzed with demographic and clinical parameters. Results: A total of 95 patients were included in the study. According to pathological responses, the distribution of RCB-0, -1, -2, -3 were 13 (13.7%), 11 (11.6%), 30 (31.6%), 41 (43.2%), respectively. Disease-free survival was significantly lower in the RCB-3 group compared to the pathological responder group (P=.01). According to multivariate analysis, RR of SUVmax was determined as an independent variable predicting extensive residual cancer burden with an optimal cut-off value of 86% (P<.05). Conclusions: We determined RR of SUVmax as an independent factor for predicting extensive residual tumor burden. We believe that RR of SUVmax is sufficient to predict pathological response in daily practice. In addition, MTV and TLG measurements do not contribute additionally to SUVmax alone and can cause unnecessary labor loss. © 2021Publication Open Access Clinicopathologic and radiologic characteristics of pleomorphic lobular breast cancer(2021-01-01) KAYA, HANDAN; BUĞDAYCI, ONUR; UĞURLU, MUSTAFA ÜMİT; ARIKAN R., AKIN TELLİ T., ALAN Ö., DEMİRCAN N. C. , BAŞOĞLU T., ERCELEP Ö., KAYA H., BUĞDAYCI O., UĞURLU M. Ü. , ÖZGEN Z., et al.Objectives: The objective of the study was to evaluate clinicopathologic and radiologic features of patients with pleomorphic lobular breast cancer (pleomorphic lobular carcinoma [PLC]). Methods: We retrospectively evaluated the clinicopathologic and radiologic features of 25 PLC patients treated in our division from 2012 to 2018. Results: Median age was 50 (range, 42–55) and 48% were postmenopausal. The presence of spiculated mass was 92%. Median tumor size was 21.9 mm (SD±12.7 mm) and axillary lymph node positivity was 44%. Frequency of microcalcification was 12% and frequency of occult breast cancer was 8%. About 72% of patients had Stage 2 or 3 disease. De novo metastatic disease was 8% and another 8% developed metastasis during follow-up. ER, PR, and Her2/neu were positive in 76%, 44%, and 8%, respectively, and 16% of patients were triple negative. All tumors were Grade III. Median Ki-67 was 22% (range 3–90%). Frequency of lymphovascular invasion was 52%. Patients were followed median of 34.5 months (95% CI, 22.2–46.8), since during this period, two patients recurred and five died, median disease-free survival and overall survival could not be reached. Conclusion: Our data suggest that patients with PLC present with poor prognostic features such as large tumor size, axillary lymph node positivity, and high lymphovascular invasion and tumor grade and Ki-67Publication Metadata only Neoadjuvan kemoterapi sonrası meme koruyucu cerrahide marjin pozitifligi ve reeksizyon oranları(2022-03-23) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; KAYA, HANDAN; BUĞDAYCI, ONUR; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., KAYA H., BUĞDAYCI O., YUMUK P. F., GÜLLÜOĞLU M. B.Publication Metadata only Conventional tools for predicting satisfactory response to neoadjuvant chemotherapy in HR+/HER2- breast cancer patients(2023-10-01) GÜLLÜOĞLU, MAHMUT BAHADIR; EREN, ÖZGÜR CAN; KAYA, HANDAN; UĞURLU, MUSTAFA ÜMİT; Oprea A. L., GÜLLÜOĞLU M. B., Aytin Y. E., EREN Ö. C., Aral C., Szekely T. B., TAŞTEKİN E., KAYA H., BADEMLER S., Karanllk H., et al.Aim: The aim of the study was to assess the role of Magee Equation 3 (MagEq3), IHC4 score, and HER2-low status in predicting \"satisfactory response (SR)\"to neoadjuvant chemotherapy (NAC) in HR+/HER2- breast cancer (BC) patients. Methods: In a retrospective study, female patients of any age with T1-4, N0-2, M0 HR+/HER2- BC who received NAC and underwent adequate locoregional surgical treatment were included. Patients were grouped according to 2 outcomes: (a) overall response to NAC in breast and axilla by using residual cancer burden (RCB) criteria and (b) axillary downstaging after NAC by using N staging. 2 cohorts for overall response were overall SR (RCB 0-1) and no SR (RCB 2-3). On the other hand, for axillary downstaging, 2 cohorts constituted from axillary SR (ypN0 and ypN0i+) and no SR (ypNmic-N3). MagEq3 and IHC4 scores were calculated from their pathological tumor slides in each patient. HER2 status was categorized as either \"no\"or \"low.\"In addition, patient age, family history, tumor histology, stage at admission, and Ki-67 status were compared between cohorts according to predefined outcomes. Results: In a total of 230 BC patients, 228 patients were included to compare according to their RCB levels. The mean age of patients with overall SR was significantly lower than those without. Patients with high Ki-67 expression, high (>30) MagEq3 score, high ICH4 quartile, and HER2-low status had significantly more overall SR. On the other hand, only patients with high Ki-67 expression had significantly more axillary SR. MagEq3 score levels, ICH4 quartiles, and HER2 status were similar between patients with axillary SR and not. Conclusion: MagEq3 and IHC4 tools seemed to be useful to predict those HR+/HER2- BC patients who are most likely to get benefit from NAC. But, only high Ki-67 expression level significantly predicted satisfactory axillary downstaging in HR+/HER2- BC patients.Publication Open Access Relationship of PPARG overexpression with prognostic parameters in papillary thyroid carcinoma(2022-02-01) ASYA, ORHAN; YUMUŞAKHUYLU, ALİ CEMAL; BAĞCI ÇULÇİ, PELİN; ŞAHİN, AKIN; OYSU, ÇAĞATAY; KAYA, HANDAN; ASYA O., YUMUŞAKHUYLU A. C., BAĞCI ÇULÇİ P., KAYA H., Gonen A., Gundogdu Y., Muradov T., ŞAHİN A., OYSU Ç.Objectives. PAX8/PPARG chromosomal rearrangement is frequently seen in thyroid cancer, and PPARG overexpression has been shown in the follicular variant of papillary thyroid carcinoma, but not in papillary thyroid carcinoma other than the follicular variant. The main aim of this study was to investigate the frequency of PPARG overexpression among papillary thyroid carcinoma and if there were any variants of papillary thyroid carcinoma with PPARG overexpression other than the follicular variant. Methods. Immunohistochemical analysis of PPARG overexpression was performed using a PPARG monoclonal antibody in a series of 111 paraffin-embedded blocks of thyroid tumours. Of the patients in our study, 100 were diagnosed with papillary thyroid carcinoma, 9 with follicular adenoma and 2 with follicular carcinoma. Results. PPARG staining was detected in 19 of the 111 cases. Sixteen patients with PPARG overexpression had papillary thyroid carcinoma and 3 had follicular adenoma. Conclusion. PPARG overexpression was detected mainly in follicular-variant papillary thyroid carcinoma. Vascular invasion, lymphatic invasion, thyroid capsule invasion and lymph node positivity were lower in patients with PPARG overexpression.Publication Metadata only The value of MRI contrast enhancement in biopsy decision of suspicious mammographic microcalcifications: a prospective multicenter study(SPRINGER, 2021) KAYA, HANDAN; Taskin, Fusun; Kalayci, Cem Burak; Tuncbilek, Nermin; Soydemir, Efe; Kurt, Nazmi; Kaya, Handan; Aribal, ErkinObjectives To investigate the inclusion of breast MRI in radiological assessment of suspicious, isolated microcalcifications detected with mammography. Methods In this prospective, multicenter study, cases with isolated microcalcifications in screening mammography were examined with dynamic contrast-enhanced MRI (DCE-MRI) before biopsy, and contrast enhancement of the relevant calcification localization was accepted as a positive finding on MRI. Six experienced breast radiologists evaluated the images and performed the biopsies. Imaging findings and histopathological results were recorded. Sensitivity, specificity, NPV, and PPV of breast MRI were calculated and compared with histopathological findings. Results Suspicious microcalcifications, which were detected by screening mammograms of 444 women, were evaluated. Of these, 276 (62.2%) were diagnosed as benign and 168 (37.8%) as malignant. Contrast enhancement was present in microcalcification localization in 325 (73.2%) of the cases. DCE-MRI was positive in all 102 invasive carcinomas and in 58 (87.9%) of 66 DCIS cases. MRI resulted in false negatives in eight DCIS cases; one was high grade and the other seven were low-to-medium grade. The false-negative rate of DCE-MRI was 4.76%. The sensitivity, specificity, PPV, and NPV for DCE-MRI for mammography-detected suspicious microcalcifications were 95.2%, 40.2%, 49.2%, and 93.3%, respectively. Conclusions In this study, all invasive cancers and all DCIS except eight cases (12.1%) were detected with DCE-MRI. DCE-MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are of low-to-medium grade.